Peter Shalit

1.5k total citations
22 papers, 639 citations indexed

About

Peter Shalit is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Peter Shalit has authored 22 papers receiving a total of 639 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Infectious Diseases, 11 papers in Virology and 8 papers in Emergency Medicine. Recurrent topics in Peter Shalit's work include HIV/AIDS drug development and treatment (15 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (11 papers). Peter Shalit is often cited by papers focused on HIV/AIDS drug development and treatment (15 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (11 papers). Peter Shalit collaborates with scholars based in United States, Spain and United Kingdom. Peter Shalit's co-authors include Elyse Tung, Jaime E. Hernández, Robin L. Fisher, Douglas Ward, J Tyler Lonergan, Vanessa C. Williams, Grace A. McComsey, Michael Sension, Joseph Gathe and Hui C. Liu and has published in prestigious journals such as JAMA, Clinical Infectious Diseases and AIDS.

In The Last Decade

Peter Shalit

20 papers receiving 606 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Shalit United States 12 521 304 245 166 47 22 639
Sirinya Teeraananchai Thailand 10 396 0.8× 221 0.7× 196 0.8× 171 1.0× 64 1.4× 27 537
José L. López-Colomés Spain 9 652 1.3× 260 0.9× 365 1.5× 227 1.4× 92 2.0× 13 857
Polly Clayden United States 14 898 1.7× 372 1.2× 451 1.8× 277 1.7× 123 2.6× 30 1.1k
Decai Zhao China 13 704 1.4× 435 1.4× 147 0.6× 411 2.5× 53 1.1× 39 847
Suzanne Siminski United States 12 352 0.7× 150 0.5× 106 0.4× 130 0.8× 61 1.3× 24 488
HB Krentz Canada 9 561 1.1× 183 0.6× 187 0.8× 401 2.4× 65 1.4× 21 654
Sean E Collins United States 15 636 1.2× 350 1.2× 246 1.0× 204 1.2× 40 0.9× 30 738
James Jansson Australia 8 472 0.9× 170 0.6× 342 1.4× 295 1.8× 88 1.9× 11 689
Paula Britto United States 15 719 1.4× 526 1.7× 170 0.7× 199 1.2× 75 1.6× 25 828
Valérie Cailleton France 6 600 1.2× 346 1.1× 298 1.2× 171 1.0× 59 1.3× 6 718

Countries citing papers authored by Peter Shalit

Since Specialization
Citations

This map shows the geographic impact of Peter Shalit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Shalit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Shalit more than expected).

Fields of papers citing papers by Peter Shalit

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Shalit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Shalit. The network helps show where Peter Shalit may publish in the future.

Co-authorship network of co-authors of Peter Shalit

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Shalit. A scholar is included among the top collaborators of Peter Shalit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Shalit. Peter Shalit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tung, Elyse, A. Dueñas, & Peter Shalit. (2025). 506. Week 26 Interim Analysis of Implementation and Delivery of Long-Acting Injectable Cabotegravir for PrEP in a Community Pharmacy Setting. Open Forum Infectious Diseases. 12(Supplement_1).
2.
Amico, K. Rivet, et al.. (2023). 1570. Exploring Antiretroviral Therapy (ART) Switch Decisions in Clinical Setting: Trio Health Mixed Methods Study. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations
3.
Mazonson, Peter, et al.. (2021). 872. Number of Sexual Partners and Patient-Reported Outcomes among Older Adults Living With HIV. Open Forum Infectious Diseases. 8(Supplement_1). S527–S528.
4.
Mazonson, Peter, et al.. (2020). Loneliness among older adults living with HIV: the “older old” may be less lonely than the “younger old”. AIDS Care. 33(3). 375–382. 24 indexed citations
5.
Tung, Elyse, et al.. (2018). Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care. Sexual Health. 15(6). 556–561. 98 indexed citations
6.
Gallant, Joel E., Graeme Moyle, Juan Berenguer, et al.. (2016). Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial. Current HIV Research. 15(3). 216–224. 5 indexed citations
7.
8.
Mills, Anthony, Gordon Crofoot, Cheryl McDonald, et al.. (2015). Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 69(4). 439–445. 121 indexed citations
9.
10.
Elion, Richard, Calvin Cohen, Joseph Gathe, et al.. (2011). Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 25(15). 1881–1886. 76 indexed citations
11.
Cohen, Calvin, Daniel S Berger, Gary Blick, et al.. (2009). Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. AIDS. 23(3). 423–426. 23 indexed citations
12.
Horne, Robert, Colin Kovacs, Christine Katlama, et al.. (2009). Prescribing and using self-injectable antiretrovirals: How concordant are physician and patient perspectives?. AIDS Research and Therapy. 6(1). 2–2. 7 indexed citations
13.
Buskin, Susan E., Gregory Pepper, Lisa M. Frenkel, et al.. (2008). Transmission Cluster of Multiclass Highly Drug-Resistant HIV-1 Among 9 Men Who Have Sex With Men in Seattle/King County, WA, 2005-2007. JAIDS Journal of Acquired Immune Deficiency Syndromes. 49(2). 205–211. 15 indexed citations
14.
Shalit, Peter, et al.. (2007). Quality of Life and Tolerability After Administration of Enfuvirtide with a Thin-Walled Needle: QUALITÉ Study. HIV Clinical Trials. 8(1). 24–35. 14 indexed citations
15.
Lonergan, J Tyler, Grace A. McComsey, Robin L. Fisher, et al.. (2004). Lack of Recurrence of Hyperlactatemia in HIV-Infected Patients Switched From Stavudine to Abacavir or Zidovudine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 36(4). 935–942. 15 indexed citations
16.
17.
Whittington, William L. H., Tarquin Collis, H. Hunter Handsfield, et al.. (2002). Sexually Transmitted Diseases and Human Immunodeficiency Virus–Discordant Partnerships among Men Who Have Sex with Men. Clinical Infectious Diseases. 35(8). 1010–1017. 38 indexed citations
18.
Scarsella, Anthony, Gregg Coodley, Peter Shalit, et al.. (2002). Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: Effect of stavudine exposure and antiretroviral experience. Advances in Therapy. 19(1). 1–8. 19 indexed citations
19.
Shalit, Peter, et al.. (2001). Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting. AIDS. 15(6). 804–805. 3 indexed citations
20.
O’Neill, Joseph F. & Peter Shalit. (1992). HEALTH CARE OF THE GAY MALE PATIENT. Primary Care Clinics in Office Practice. 19(1). 191–201. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sirinya Teeraananchai Breakdown of academic impact, for papers by José L. López-Colomés Breakdown of academic impact, for papers by Polly Clayden Breakdown of academic impact, for papers by Decai Zhao Breakdown of academic impact, for papers by Suzanne Siminski Breakdown of academic impact, for papers by HB Krentz Breakdown of academic impact, for papers by Sean E Collins Breakdown of academic impact, for papers by James Jansson Breakdown of academic impact, for papers by Paula Britto Breakdown of academic impact, for papers by Valérie Cailleton
Rankless by CCL
2026